Ignacio Melero
Professor of Immunology at the University of Navarra, CIMA researcher and co-director of the Department of Immunology and Immunotherapy at the Clínica Universidad de Navarra.
The most interesting aspect of the study is that intracavitary locoregional delivery is the way forward. This intracavitary or intratumoral route of administration can optimise CAR-T cell performance against solid tumours with maximum exposure. In the case of intracranial administration, it must be taken into account that inflammation of the tumour (tumouritis) will occur and that there are risks of intracranial hypertension requiring intensive monitoring and treatment if this adverse effect occurs. On the other hand, other side effects such as systemic cytokine release syndromes (cytokine storms) do not occur via this route.
Other groups such as Marcela Maus' group have used the intracranial route in patients with glioblastoma multiforme with encouraging results. We have recently published a review on the local approach in the use of adoptive cell therapy that may be useful.